– The Company Plans to Pursue Registration and is Exploring Partnering or Licensing Opportunities for PEDMARK ® in Japan Based Upon These Results – RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE ...
Hosted on MSN
Fennec Pharmaceuticals supports new trial for hearing loss prevention in cancer treatment
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The ...
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) on Tuesday shared topline results from the investigator-initiated Phase 2/3 STS-J01 trial of Pedmark (sodium thiosulfate injection) to reduce ...
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback